Market Research Logo

iBio, Inc. - Product Pipeline Review - 2016

iBio, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘iBio, Inc. - Product Pipeline Review - 2016’, provides an overview of the iBio, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
  • The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses iBio, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features iBio, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate iBio, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding iBio, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


iBio, Inc. Snapshot
iBio, Inc. Overview
Key Information
Key Facts
iBio, Inc. - Research and Development Overview
Key Therapeutic Areas
iBio, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
iBio, Inc. - Pipeline Products Glance
iBio, Inc. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
iBio, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
iBio, Inc. - Drug Profiles
anthrax vaccine
Product Description
Mechanism of Action
R&D Progress
HAI-05
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H1N1] vaccine
Product Description
Mechanism of Action
R&D Progress
malaria vaccine
Product Description
Mechanism of Action
R&D Progress
NaAPR1M-74
Product Description
Mechanism of Action
R&D Progress
anthrax + plague vaccine
Product Description
Mechanism of Action
R&D Progress
human papillomavirus [Serotype 16] vaccine
Product Description
Mechanism of Action
R&D Progress
IBIOCFB-03
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Anthrax
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit Neuraminidase for Influenza
Product Description
Mechanism of Action
R&D Progress
palivizumab biosimilar
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema
Product Description
Mechanism of Action
R&D Progress
yellow fever vaccine
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H7N9] vaccine
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Oncology
Product Description
Mechanism of Action
R&D Progress
trypanosomiasis vaccine
Product Description
Mechanism of Action
R&D Progress
iBio, Inc. - Pipeline Analysis
iBio, Inc. - Pipeline Products by Target
iBio, Inc. - Pipeline Products by Route of Administration
iBio, Inc. - Pipeline Products by Molecule Type
iBio, Inc. - Pipeline Products by Mechanism of Action
iBio, Inc. - Recent Pipeline Updates
iBio, Inc. - Dormant Projects
iBio, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
iBio, Inc., Key Information
iBio, Inc., Key Facts
iBio, Inc. - Pipeline by Indication, 2016
iBio, Inc. - Pipeline by Stage of Development, 2016
iBio, Inc. - Monotherapy Products in Pipeline, 2016
iBio, Inc. - Combination Treatment Modalities in Pipeline, 2016
iBio, Inc. - Phase I, 2016
iBio, Inc. - Preclinical, 2016
iBio, Inc. - Discovery, 2016
iBio, Inc. - Pipeline by Target, 2016
iBio, Inc. - Pipeline by Route of Administration, 2016
iBio, Inc. - Pipeline by Molecule Type, 2016
iBio, Inc. - Pipeline Products by Mechanism of Action, 2016
iBio, Inc. - Recent Pipeline Updates, 2016
iBio, Inc. - Dormant Developmental Projects,2016
List of Figures
iBio, Inc. - Pipeline by Top 10 Indication, 2016
iBio, Inc. - Pipeline by Stage of Development, 2016
iBio, Inc. - Monotherapy Products in Pipeline, 2016
iBio, Inc. - Pipeline by Target, 2016
iBio, Inc. - Pipeline by Route of Administration, 2016
iBio, Inc. - Pipeline by Molecule Type, 2016
iBio, Inc. - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report